United Therapeutics (UTHR) Non-Current Assets (2009 - 2026)

United Therapeutics has disclosed Non-Current Assets across 18 years of filings, most recently posting $3.7 billion for Q2 2026.

• In Q2 2026, Non-Current Assets fell 8.45% year-over-year to $3.7 billion; the TTM figure through Jun 2026 stood at $15.6 billion (up 7.69% YoY), while the FY2025 annual figure was $4.2 billion, up 19.7% from the prior year.
• Non-Current Assets came in at $3.7 billion for Q2 2026 at United Therapeutics, down from $3.8 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $4.2 billion in Q4 2025 to a low of $2.7 billion in Q4 2022.
• Average Non-Current Assets over 5 years is $3.4 billion, with a median of $3.5 billion recorded in 2023.
• Year-over-year, Non-Current Assets soared 35.73% in 2023 and declined 12.4% in 2024.
• Over 5 years, Non-Current Assets stood at $2.7 billion in 2022, then soared by 35.73% to $3.6 billion in 2023, then retreated by 3.48% to $3.5 billion in 2024, then increased by 19.7% to $4.2 billion in 2025, then fell by 10.56% to $3.7 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $3.7 billion in Q2 2026, $3.8 billion in Q1 2026, and $4.2 billion in Q4 2025.